NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

RecruitingPhase 3

Sponsor: Eli Lilly and Company

Conditions: Juvenile Idiopathic Arthritis

Interventions: Baricitinib

Countries: Argentina, Australia, Austria, Belgium, Brazil, China, Czechia, Denmark

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Eligibility overview

Sex: ALL

Age: 1 Year to 18 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participants must have completed a previous study of baricitinib for the treatment of JIA.

Exclusion Criteria:

* Participants must not have had a permanent discontinuation of baricitinib in the prior study.
* Participants must have not developed an allergy to baricitinib.

Locations (78)

Rosario, Argentina
SAN M. de Tucuman, Argentina
Melbourne, Australia
Perth, Australia
Westmead, Australia
Bregenz, Austria
Brussels, Belgium
Ghent, Belgium
Leuven, Belgium
Botucatu, Brazil
São Paulo, Brazil
São Paulo, Brazil
Beijing, China
Chongqing, China
Nanjing, China
Suzhou, China
Brno, Czechia
Prague, Czechia
Prague, Czechia
Aarhus, Denmark
Bron, France
Le Kremlin-Bicêtre, France
Nîmes, France
Paris, France
Poitiers, France
Berlin, Germany
Berlin, Germany
Hamburg, Germany
Heidelberg, Germany
Sankt Augustin, Germany
+ 48 more on CT.gov